SMPD3 and Alzheimer disease: In fact, EVs have been proposed as facilitators of AD pathology spreading in AD, with their secretion suppression via Neutral sphingomyelinase 2 (nSMase2) blockade as a therapeutic approach to halt pathology spreading in mouse models [17].